Elevance (ELV) Faces Rising Medicaid Cost Pressure
Elevance Health (ELV) posted a mixed quarter—EPS beat but revenue slightly missed—while management warned of elevated Medicaid and ACA medical costs that threaten near-term margin improvement. The stock sold off following cost guidance, an institutional trimming was reported, and a modest dividend raise underscores cash resilience. Key watchpoints: medical-cost trends, updated guidance, and peer comparisons.
